Retinal Disease Therapeutics Market Size, Share, Growth Analysis, By Disorder, By Disorder Type, By Treatment Techniques, By Route Of Administration, By End-Users, By Distribution Channel, By Region - Industry Forecast 2024-2031

Retinal Disease Therapeutics Market size was valued at USD 12.57 Billion in 2023 and is poised to grow from USD 13.74 Billion in 2024 to USD 28.08 Billion by 2032, growing at a CAGR of 9.3% during the forecast period (2025-2032).

The prevalence of retinal disorders is escalating globally, impacting over 253 million people and posing significant challenges for healthcare systems, particularly as the population ages. With 81% of individuals affected being over 50, the rising life expectancy is intensifying demand in the ophthalmic care sector. The incidence of retinal diseases, notably diabetic retinopathy and diabetic macular edema, is surging, especially in developing countries where diabetes rates are increasing. The market is anticipated to expand during the forecast period, driven by the growing number of specialized professionals capable of addressing these conditions. Furthermore, enhanced reimbursement policies are expected to facilitate market growth by 2028, assisting with the high costs associated with retinal disease treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Retinal Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Retinal Disease Therapeutics Market Segmental Analysis

Global Retinal Disease Therapeutics Market is segmented by disorder, disorder type, treatment techniques, route of administration, end-users, distribution channel and region. Based on disorder, the market is segmented into macular degeneration, diabetic eye disease, retinal detachment, retinoblastoma, macular pucker, macular hole and floaters. Based on disorder type, the market is segmented into genetic and age related. Based on treatment techniques, the market is segmented into laser, freezing, implanting, indenting, pneumatic retinopexy, scleral buckling and vitrectomy. Based on route of administration, the market is segmented into oral, topical, intravitreal and others. Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, home healthcare and others. Based on distribution channel, the market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Retinal Disease Therapeutics Market

The growth of the retinal disease therapeutics market is significantly influenced by the rising prevalence of eye disorders, especially in developed nations. Notably, the American Academy of Ophthalmology reported that as of 2016, around 93 million people globally were affected by diabetic retinopathy, with 4.2 million cases in the United States alone. Projections by the NCBI estimate that by 2040, Europe could see between 14.9 to 21.5 million individuals with early Age-Related Macular Degeneration (AMD) and up to 4.8 million with late-stage AMD. Efforts to raise awareness about eye health and encourage early treatment, particularly in developing regions, are expected to further propel the growth of the retinal disease therapeutics market in the upcoming years.

Restraints in the Retinal Disease Therapeutics Market

The growth of the Retinal Disease Therapeutics market faces several challenges, primarily due to the high costs associated with treatment options for retinal diseases. The financial burden of these therapies can deter patients from seeking necessary care. Furthermore, patients often report experiencing short-term side effects, as well as potential long-term issues like infections and inflammation following procedures like laser eye surgery. Surgical techniques, such as pneumatic retinopexy, carry risks, including unintended scleral perforation, which may further influence patient choices. Additionally, inadequate healthcare infrastructure in developing countries poses significant barriers to market expansion, limiting access to effective therapies.

Market Trends of the Retinal Disease Therapeutics Market

The retinal disease therapeutics market is witnessing a significant upward trend, fueled by the emergence of advanced technologies such as gene therapy. Innovations like Luxturna, targeting inherited retinal disorders through RPE65 gene mutations, exemplify the progress being made in this field. As numerous gene therapies involving recombinant viral vectors advance through clinical trials, their potential to ameliorate conditions like Leber's congenital amaurosis is garnering attention and investment. Between 2022 and 2028, this focus on high-end therapeutic solutions is expected to drive market growth, paving the way for improved treatment outcomes and enhanced quality of life for patients suffering from retinal diseases.